相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Multi-omic analysis reveals divergent molecular events in scarring and regenerative wound healing
Shamik Mascharak et al.
CELL STEM CELL (2022)
Human alveolar type 2 epithelium transdifferentiates into metaplastic KRT5+ basal cells
Jaymin J. Kathiriya et al.
NATURE CELL BIOLOGY (2022)
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial
Manas Kumar Panigrahi et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2022)
Multiplatform Single-Cell Analysis Identifies Immune Cell Types Enhanced in Pulmonary Fibrosis
Ana P. M. Serezani et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2022)
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2022)
Expansion of Fc gamma Receptor IIIa-Positive Macrophages, Ficolin 1-Positive Monocyte-Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis
Dan Xue et al.
ARTHRITIS & RHEUMATOLOGY (2022)
Driving Role of Interleukin-2-Related Regulatory CD4+T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic Sclerosis
Camelia Frantz et al.
ARTHRITIS & RHEUMATOLOGY (2022)
Safety, tolerability, and anti-fibrotic efficacy of the CBP/I3-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study
Kiminori Kimura et al.
EBIOMEDICINE (2022)
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Moshe Talpaz et al.
LEUKEMIA (2021)
TGFβ biology in cancer progression and immunotherapy
Rik Derynck et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Backstage players of fibrosis: NOX4, mTOR, HDAC, and S1P; companions of TGF-β
Alexis Paulina Jimenez-Uribe et al.
CELLULAR SIGNALLING (2021)
TGF-β-induced fibrosis: A review on the underlying mechanism and potential therapeutic strategies
Chun Hao Ong et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven M. Francque et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Transcriptional analysis of cystic fibrosis airways at single-cell resolution reveals altered epithelial cell states and composition
Gianni Carraro et al.
NATURE MEDICINE (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease
Eleanor Valenzi et al.
FRONTIERS IN IMMUNOLOGY (2021)
Next Generation Therapeutics for the Treatment of Myelofibrosis
Douglas Tremblay et al.
CELLS (2021)
Glucagon-like peptide-1 (GLP-1) improved diabetic lung fibrosis via AMPK and microRNA-27a (miR-27a)
Jia Liu et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM alpha), versus placebo in patients with non-alcoholic fatty liver disease
Atsushi Nakajima et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis
Animesh Pardanani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
FGF/FGFR signaling: From lung development to respiratory diseases
Lehe Yang et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2021)
Single-Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell-Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice
Wu Yang et al.
HEPATOLOGY (2021)
Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling
Vik Meadows et al.
HEPATOLOGY (2021)
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
Francisco Cervantes et al.
LEUKEMIA (2021)
Epithelial-Mesenchymal Transition (EMT): The Type-2 EMT in Wound Healing, Tissue Regeneration and Organ Fibrosis
Guya D. Marconi et al.
CELLS (2021)
TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis
Lilian Varricchio et al.
JCI INSIGHT (2021)
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial
Samer Gawrieh et al.
HEPATOLOGY (2021)
Global incidence and prevalence of idiopathic pulmonary fibrosis
Toby M. Maher et al.
RESPIRATORY RESEARCH (2021)
Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development
Justin D. Schumacher et al.
HEPATOLOGY (2020)
Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis
Pavel Drevinek et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH)
Menso J. Westerouen Van Meeteren et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Janus kinase inhibitors role in bone remodeling
Nicola Maruotti et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Targeting metabolic dysregulation for fibrosis therapy
Xiao Zhao et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
Luca Richeldi et al.
LANCET RESPIRATORY MEDICINE (2020)
Lysyl oxidases: linking structures and immunity in the tumor microenvironment
Paolo Tenti et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
MKL1 mediates TGF-β-induced CTGF transcription to promote renal fibrosis
Lei Mao et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Impaired Myofibroblast Dedifferentiation Contributes to Nonresolving Fibrosis in Aging
Kosuke Kato et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2020)
Mechanisms of liver fibrosis and its role in liver cancer
Debanjan Dhar et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2020)
Cilofexor, a NonsteroidalFXRAgonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel et al.
HEPATOLOGY (2020)
GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals
Laerke S. Gasbjerg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2020)
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Boris Bikbov et al.
LANCET (2020)
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Boris Hinz et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
Molecular interactions of full-length and truncated GIP peptides with the GIP receptor - A comprehensive review
Maria Buur Nordskov Gabe et al.
PEPTIDES (2020)
Non-canonical (non-SMAD2/3) TGF-β signaling in fibrosis: Mechanisms and targets
Kenneth W. Finnson et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2020)
Single-cell analysis based dissection of clonality in myelofibrosis
Elena Mylonas et al.
NATURE COMMUNICATIONS (2020)
Acute kidney injury and maladaptive tubular repair leading to renal fibrosis
Samuel M. -W. Yu et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2020)
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman et al.
DIABETES CARE (2020)
Incretin combination therapy for the treatment of non-alcoholic steatohepatitis
Aimo Kannt et al.
DIABETES OBESITY & METABOLISM (2020)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
Michael K. Badman et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Alveolar Epithelial Type II Cells as Drivers of Lung Fibrosis in Idiopathic Pulmonary Fibrosis
Tanyalak Parimon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Sander Lefere et al.
JOURNAL OF HEPATOLOGY (2020)
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy
Niu Shin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content
Yusuke Sasaki et al.
SCIENTIFIC REPORTS (2020)
A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
Ping An et al.
LIVER INTERNATIONAL (2020)
Design, synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy
Yuqin Yao et al.
ACTA PHARMACEUTICA SINICA B (2020)
TGF-β Signaling
Kalliopi Tzavlaki et al.
BIOMOLECULES (2020)
The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis
Nahum Mendez-Sanchez et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Activation of ERK1/2-mTORC1-NOX4 mediates TGF-β1-induced epithelial-mesenchymal transition and fibrosis in retinal pigment epithelial cells
Soo-Jin Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease
Alain Lescoat et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis
Taylor S. Adams et al.
SCIENCE ADVANCES (2020)
An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
Jia Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Leiluo Geng et al.
NATURE REVIEWS ENDOCRINOLOGY (2020)
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Theo Vos et al.
LANCET (2020)
The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model
Linfu Liu et al.
PLOS ONE (2020)
The T Cell Receptor Immune Repertoire Protects the Liver From Reconsitution
Qing Liang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
Michelle L. Boland et al.
NATURE METABOLISM (2020)
Artificial MicroRNA-Mediated Tgfbr2 and Pdgfrb Co-Silencing Ameliorates Carbon Tetrachloride-Induced Hepatic Fibrosis in Mice
Yan Jiang et al.
HUMAN GENE THERAPY (2019)
Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis
Liudi Yao et al.
CELL DEATH AND DIFFERENTIATION (2019)
Burden of liver diseases in the world
Sumeet K. Asrani et al.
JOURNAL OF HEPATOLOGY (2019)
Developmental pathways in the pathogenesis of lung fibrosis
Diptiman Chanda et al.
MOLECULAR ASPECTS OF MEDICINE (2019)
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Maurizio Parola et al.
MOLECULAR ASPECTS OF MEDICINE (2019)
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors
Gregory L. Beatty et al.
ONCOLOGIST (2019)
VEGF in Signaling and Disease: Beyond Discovery and Development
Rajendra S. Apte et al.
CELL (2019)
Methyl ferulic acid attenuates liver fibrosis and hepatic stellate cell activation through the TGF-β1/Smad and NOX4/ROS pathways
Qi Cheng et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2019)
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Pauline T. Lukey et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma
Pei-Suen Tsou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Janus kinases to jakinibs: from basic insights to clinical practice
Massimo Gadina et al.
RHEUMATOLOGY (2019)
TGF-β activation impairs fibroblast ability to support adult lung epithelial progenitor cell organoid formation
John-Poul Ng-Blichfeldt et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2019)
Lysyl oxidase-like 2 (LOXL2)-mediated cross-linking of tropoelastin
Christian E. H. Schmelzer et al.
FASEB JOURNAL (2019)
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials
Scott C. Bell et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Single-cell expression profiling reveals dynamic flux of cardiac stromal,vascular and immune cells in health and injury
Nona Farbehi et al.
ELIFE (2019)
Neuropilin-1 aggravates liver cirrhosis by promoting angiogenesis via VEGFR2-dependent PI3K/Akt pathway in hepatic sinusoidal endothelial cells
Le Wang et al.
EBIOMEDICINE (2019)
Inhibition of hyperglycolysis in mesothelial cells prevents peritoneal fibrosis
Meijun Si et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
G. J. Connett
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Metabolite Profiling of the Antisense Oligonucleotide Eluforsen Using Liquid Chromatography-Mass Spectrometry
Jaeah Kim et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Lymphangiogenesis in kidney and lymph node mediates renal inflammation and fibrosis
Guangchang Pei et al.
SCIENCE ADVANCES (2019)
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens et al.
CELL METABOLISM (2019)
Lysyl oxidases: from enzyme activity to extracellular matrix cross-links
Sylvain D. Vallet et al.
EXTRACELLULAR MATRIX (2019)
IL-1β dominates the promucin secretory cytokine profile in cystic fibrosis
Gang Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
GLP-1: Molecular mechanisms and outcomes of a complex signaling system
Nicholas K. Smith et al.
NEUROCHEMISTRY INTERNATIONAL (2019)
Going Back to the Biology of FGF21: New Insights
Jo E. Lewis et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2019)
Myelofibrosis in 2019: moving beyond JAK2 inhibition
Michael Schieber et al.
BLOOD CANCER JOURNAL (2019)
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
Bruno Crestani et al.
LANCET RESPIRATORY MEDICINE (2019)
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Hong Sheng Cheng et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Resolving the fibrotic niche of human liver cirrhosis at single-cell level
P. Ramachandran et al.
NATURE (2019)
Shared and distinct mechanisms of fibrosis
Joerg H. W. Distler et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
Motoyasu Kato et al.
SCIENTIFIC REPORTS (2019)
Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis
Paul A. Reyfman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Pathology and natural history of organ fibrosis
Joaquim Majo et al.
CURRENT OPINION IN PHARMACOLOGY (2019)
Structure and mechanisms of ROS generation by NADPH oxidases
Francesca Magnani et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2019)
Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage
Dvir Aran et al.
NATURE IMMUNOLOGY (2019)
Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis
Hee-Young Yoon et al.
RESPIRATION (2019)
Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis
Kevin K. Brown et al.
RESPIRATORY MEDICINE (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry
Monika Zurkova et al.
RESPIRATORY RESEARCH (2019)
Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents
Eloy D. Hernandez et al.
HEPATOLOGY COMMUNICATIONS (2019)
European Society of Cardiology: Cardiovascular Disease Statistics 2017
Adam Timmis et al.
EUROPEAN HEART JOURNAL (2018)
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
Rohit Loomba et al.
HEPATOLOGY (2018)
Current and future pharmacological therapies for NAFLD/NASH
Yoshio Sumida et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Dual PPAR/agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
Mukul R. Jain et al.
LIVER INTERNATIONAL (2018)
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair Younossi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR
Scott H. Donaldson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Impact of Lung Function Decline on Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF)
M. Kreuter et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Lysyl Oxidase-Like 1 Protein Deficiency Protects Mice from Adenoviral Transforming Growth Factor-beta 1-induced Pulmonary Fibrosis
Pierre-Simon Bellaye et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2018)
Inhibition of canonical WNT signaling pathway by β-catenin/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12
Busra Ozturk Akcora et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk
Faten A. Al-Aqil et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Enhanced expression and distinctive characterization of a long-acting FGF21 and its potential to alleviate nonalcoholic steatohepatitis
Jun Yin et al.
BIOCHIMIE (2018)
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study
Philip D. Ambery et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2018)
Future applications of FGF/FGFR inhibitors in cancer
Gaia Cristina Ghedini et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Amphiregulin-Producing Pathogenic Memory T Helper 2 Cells Instruct Eosinophils to Secrete Osteopontin and Facilitate Airway Fibrosis
Yuki Morimoto et al.
IMMUNITY (2018)
Integrin αvβ6: Structure, function and role in health and disease
Leeni Koivisto et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2018)
VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease
Shaney L. Barratt et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
Jessica Lawrence et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
SFRP2/DPP4 and FMO1/LSP1 Define Major Fibroblast Populations in Human Skin
Tracy Tabib et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis
Xueqing Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation
Hyun Young Koo et al.
JOURNAL OF PATHOLOGY (2018)
The PDGF/PDGFR pathway as a drug target
Natalia Papadopoulos et al.
MOLECULAR ASPECTS OF MEDICINE (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Idiopathic Pulmonary Fibrosis
David J. Lederer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype
Gali Epstein Shochet et al.
RESPIROLOGY (2018)
Eosinophil depletion suppresses radiation-induced small intestinal fibrosis
Naoki Takemura et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
M. Molina-Molina et al.
BMC PULMONARY MEDICINE (2018)
Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis
Ting Xie et al.
CELL REPORTS (2018)
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Margaret Neighbors et al.
LANCET RESPIRATORY MEDICINE (2018)
S100a4 Is Secreted by Alternatively Activated Alveolar Macrophages and Promotes Activation of Lung Fibroblasts in Pulmonary Fibrosis
Wei Zhang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2018)
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial
John Mascarenhas et al.
JAMA ONCOLOGY (2018)
Runt-Related Transcription Factor 1 (RUNX1) Promotes TGF-β-Induced Renal Tubular Epithelial-to-Mesenchymal Transition (EMT) and Renal Fibrosis through the PI3K Subunit p110δ
Tong Zhou et al.
EBIOMEDICINE (2018)
Knockdown of LOXL1 inhibits TGF-beta 1-induced proliferation and fibrogenesis of hepatic stellate cells by inhibition of Smad2/3 phosphorylation
Li Ma et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
FXR modulators for enterohepatic and metabolic diseases
Hong Wang et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
CXCL6-EGFR-induced Kupffer cells secrete TGF-β1 promoting hepatic stellate cell activation via the SMAD2/BRD4/C-MYC/EZH2 pathway in liver fibrosis
Xiaobo Cai et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor
William J. Zacharias et al.
NATURE (2018)
A revised airway epithelial hierarchy includes CFTR-expressing ionocytes
Daniel T. Montoro et al.
NATURE (2018)
FXR Inhibits Endoplasmic Reticulum Stress-Induced NLRP3 Inflammasome in Hepatocytes and Ameliorates Liver Injury
Chang Yeob Han et al.
CELL REPORTS (2018)
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Spencer L. G. James et al.
LANCET (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017
Gregory A. Roth et al.
LANCET (2018)
Clinical and genetic characteristics of cystic fibrosis in CHINESE patients: a systemic review of reported cases
Xiaobei Guo et al.
ORPHANET JOURNAL OF RARE DISEASES (2018)
Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy
M. Pilar Valdecantos et al.
SCIENTIFIC REPORTS (2018)
South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Shaney L. Barratt et al.
FRONTIERS IN PHARMACOLOGY (2018)
CTGF in kidney fibrosis and glomerulonephritis
Naohiro Toda et al.
INFLAMMATION AND REGENERATION (2018)
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Hee-Young Yoon et al.
RESPIRATORY RESEARCH (2018)
Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis
Mareike Lehmann et al.
RESPIRATORY RESEARCH (2018)
Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
Pilar Rivera-Ortega et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2018)
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis Results of the INJOURNEY Trial
Carlo Vancheri et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF)
Shaney L. Barratt et al.
RESPIRATORY RESEARCH (2018)
TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung
Swati Bhattacharyya et al.
JCI INSIGHT (2018)
Vascular endothelial growth factor control mechanisms in skeletal growth and repair
Kai Hu et al.
DEVELOPMENTAL DYNAMICS (2017)
Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study
Yani Liu et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2017)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
Martin Kolb et al.
THORAX (2017)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
Hepatic FXR/SHP Axis Modulates Systemic Glucose and Fatty Acid Homeostasis in Aged Mice
Kang Ho Kim et al.
HEPATOLOGY (2017)
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Vanessa Dubois et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis
Ruben A. Mesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics
Hua-Zhong Ying et al.
MOLECULAR MEDICINE REPORTS (2017)
Mechanisms of hepatic stellate cell activation
Takuma Tsuchida et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
WNT signalling in prostate cancer
Virginia Murillo-Garzon et al.
NATURE REVIEWS UROLOGY (2017)
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Steven M. Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis
Daisy Y. Shu et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2017)
Selective inhibitor of Wnt/β-catenin/CBP signaling ameliorates hepatitis C virus-induced liver fibrosis in mouse model
Yuko Tokunaga et al.
SCIENTIFIC REPORTS (2017)
Idiopathic pulmonary fibrosis
Fernando J. Martinez et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial
Kiminori Kimura et al.
EBIOMEDICINE (2017)
Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
Yasushi Honda et al.
SCIENTIFIC REPORTS (2017)
Distinct Mesenchymal Lineages and Niches Promote Epithelial Self-Renewal and Myofibrogenesis in the Lung
Jarod A. Zepp et al.
CELL (2017)
Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis
Lynne A. Murray et al.
JCI INSIGHT (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone
Larissa Knueppel et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2017)
CFTR potentiators: from bench to bedside
Kang-Yang Jih et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases
Junichiro Sonoda et al.
HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION (2017)
PPARs and nonalcoholic fatty liver disease
Kim H. H. Liss et al.
BIOCHIMIE (2017)
JAK-STAT signalling and the atrial fibrillation promoting fibrotic substrate
Yu Chen et al.
CARDIOVASCULAR RESEARCH (2017)
WNT-5A regulates TGF-β-related activities in liver fibrosis
Leonie Beljaars et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2017)
Mechanisms and consequences of Jak-STAT signaling in the immune system
Alejandro V. Villarino et al.
NATURE IMMUNOLOGY (2017)
Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR
Carlos E. Milla et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Dietary Saturated Fat Promotes Development of Hepatic Inflammation Through Toll-Like Receptor 4 in Mice
Alton G. Sutter et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2016)
Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its Control by TGF-β and WNT7B in Human Lung Fibroblasts
Donna R. Newman et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2016)
Lung Pericytes and Resident Fibroblasts Busy Multitaskers
Luke Barron et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro
Audrey Joannes et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2016)
Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis
David N. O'Dwyer et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2016)
The PDGF system and its antagonists in liver fibrosis
Erawan Borkham-Kamphorst et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2016)
Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression
Enas A. Abd El-Haleim et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
PDGF-A and PDGF-B induces cardiac fibrosis in transgenic mice
Radiosa Gallini et al.
EXPERIMENTAL CELL RESEARCH (2016)
Lysyl Oxidase Isoforms and Potential Therapeutic Opportunities for Fibrosis and Cancer
Philip C. Trackman
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
Alexandra Montagner et al.
GUT (2016)
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
Abdallah Abou Zahr et al.
HAEMATOLOGICA (2016)
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis
Mei Xiang et al.
JOURNAL OF HEPATOLOGY (2016)
DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity
Lanfeng Xie et al.
JOURNAL OF HEPATOLOGY (2016)
Fibroblast growth factor-1 attenuates TGF-β1-induced lung fibrosis
Chiko Shimbori et al.
JOURNAL OF PATHOLOGY (2016)
Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013
Maigeng Zhou et al.
LANCET (2016)
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of aecurrency sign50 % of Predicted Value
Wim A. Wuyts et al.
LUNG (2016)
Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice
Jiurong Liang et al.
NATURE MEDICINE (2016)
Ten years of anti-vascular endothelial growth factor therapy
Napoleone Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
TGF-β: the master regulator of fibrosis
Xiao-ming Meng et al.
NATURE REVIEWS NEPHROLOGY (2016)
Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways
Bi Chen et al.
RESPIROLOGY (2016)
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Paul F. Mercer et al.
THORAX (2016)
MCPIP1 Regulates Alveolar Macrophage Apoptosis and Pulmonary Fibroblast Activation After in vitro Exposure to Silica
Xingang Wang et al.
TOXICOLOGICAL SCIENCES (2016)
Therapeutics Targeting FGF Signaling Network in Human Diseases
Masaru Katoh
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins
Ian B. Robertson et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2016)
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
Abdallah Abou Zahr et al.
HAEMATOLOGICA (2016)
Cell surface receptors for CCN proteins
Lester F. Lau
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2016)
Targeting the PDGF-B/PDGFR-β Interface with Destruxin A5 to Selectively Block PDGF-BB/PDGFR-ββ Signaling and Attenuate Liver Fibrosis
Xingqi Wang et al.
EBIOMEDICINE (2016)
Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis
Yan Xu et al.
JCI INSIGHT (2016)
A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)
Takekazu Iwata et al.
RESPIRATORY RESEARCH (2016)
NADPH Oxidase Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft Recruitment
Suvarthi Das et al.
AMERICAN JOURNAL OF PATHOLOGY (2015)
Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice
Shu Chen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2015)
Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology
Alicia K. Olivier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2015)
Idiopathic Pulmonary Fibrosis in United States Automated Claims Incidence, Prevalence, and Algorithm Validation
Daina B. Esposito et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Rami S. Komrokji et al.
BLOOD (2015)
PDGF-D signaling in portal myofibroblasts and hepatic stellate cells proves identical to PDGF-B via both PDGF receptor type α and β
Erawan Borkham-Kamphorst et al.
CELLULAR SIGNALLING (2015)
CD147 promotes liver fibrosis progression via VEGF-A/VEGFR2 signalling-mediated cross-talk between hepatocytes and sinusoidal endothelial cells
Zhaoyong Yan et al.
CLINICAL SCIENCE (2015)
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Lutz Wollin et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Hepatic Inflammation and Fibrosis: Functional Links and Key Pathways
Ekihiro Seki et al.
HEPATOLOGY (2015)
Treatment with PPARδ agonist alleviates non-alcoholic fatty liver disease by modulating glucose and fatty acid metabolic enzymes in a rat model
Xiuli Li et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2015)
NAFLD: A multisystem disease
Christopher D. Byrne et al.
JOURNAL OF HEPATOLOGY (2015)
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
Michal Pawlak et al.
JOURNAL OF HEPATOLOGY (2015)
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox
Carmel B. Nanthakumar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
C. E. Wainwright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Fibrosis - A Common Pathway to Organ Injury and Failure
Don C. Rockey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Resolution of Liver Fibrosis: Basic Mechanisms and Clinical Relevance
Prakash Ramachandran et al.
SEMINARS IN LIVER DISEASE (2015)
Pulmonary macrophages: key players in the innate defence of the airways
Adam J. Byrne et al.
THORAX (2015)
The Fibroblast Growth Factor signaling pathway
David M. Ornitz et al.
WILEY INTERDISCIPLINARY REVIEWS-DEVELOPMENTAL BIOLOGY (2015)
Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development
Iker Uriarte et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Hepatic Mitogen-Activated Protein Kinase Phosphatase 1 Selectively Regulates Glucose Metabolism and Energy Homeostasis
Ahmed Lawan et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2014)
VEGF-VEGFR Signals in Health and Disease
Masabumi Shibuya
BIOMOLECULES & THERAPEUTICS (2014)
The PPARα-FGF21 Hormone Axis Contributes to Metabolic Regulation by the Hepatic JNK Signaling Pathway
Santiago Vernia et al.
CELL METABOLISM (2014)
Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
Sara C. Meyer et al.
CLINICAL CANCER RESEARCH (2014)
The Metabolic Syndrome and Chronic Liver Disease
Matteo Rosselli et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets
Ffolliott M. Fisher et al.
GASTROENTEROLOGY (2014)
Cystic fibrosis: An update for clinicians. Part 2: Hepatobiliary and pancreatic manifestations
Oren Ledder et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
The inflammatory response in myocardial injury, repair, and remodelling
Nikolaos G. Frangogiannis
NATURE REVIEWS CARDIOLOGY (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Nox4 and redox signaling mediate TGF-β-induced endothelial cell apoptosis and phenotypic switch
F. Yan et al.
CELL DEATH & DISEASE (2014)
Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis
Lutz Wollin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Platelet-Derived Growth Factor (PDGF)-C Neutralization Reveals Differential Roles of PDGF Receptors in Liver and Kidney Fibrosis
Ina V. Martin et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Rationale for Targeting the PI3K/Akt/mTOR Pathway in Myeloproliferative Neoplasms
Niccolò Bartalucci et al.
Clinical Lymphoma Myeloma & Leukemia (2013)
Transforming Growth Factor-β (TGF-β)-mediated Connective Tissue Growth Factor (CTGF) Expression in Hepatic Stellate Cells Requires Stat3 Signaling Activation
Yan Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Type 2 alveolar cells are stem cells in adult lung
Christina E. Barkauskas et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
FXR signaling in the enterohepatic system
Tsutomu Matsubara et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2013)
PPARγ signaling and metabolism: the good, the bad and the future
Maryam Ahmadian et al.
NATURE MEDICINE (2013)
Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Francisco A. Monsalve et al.
MEDIATORS OF INFLAMMATION (2013)
Pneumoconiosis
Paul Cullinan et al.
PRIMARY CARE RESPIRATORY JOURNAL (2013)
Involvement of PDGF in Fibrosis and Scleroderma: Recent Insights from Animal Models and Potential Therapeutic Opportunities
Tomoaki Iwayama et al.
CURRENT RHEUMATOLOGY REPORTS (2013)
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
James L. Trevaskis et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Regulation of Transforming Growth Factor-β1-driven Lung Fibrosis by Galectin-3
Alison C. MacKinnon et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
CCN2/CTGF binds to fibroblast growth factor receptor 2 and modulates its signaling
Eriko Aoyama et al.
FEBS LETTERS (2012)
Role of Differentiation of Liver Sinusoidal Endothelial Cells in Progression and Regression of Hepatic Fibrosis in Rats
Guanhua Xie et al.
GASTROENTEROLOGY (2012)
Interactions Between β-Catenin and Transforming Growth Factor-β Signaling Pathways Mediate Epithelial-Mesenchymal Transition and Are Dependent on the Transcriptional Co-activator cAMP-response Element-binding Protein (CREB)-binding Protein (CBP)
Beiyun Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Activation of the Farnesoid X Receptor Induces Hepatic Expression and Secretion of Fibroblast Growth Factor 21
Holly A. Cyphert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study
Malin Hultcrantz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Christopher J. L. Murray et al.
LANCET (2012)
GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
Su-Jin Kim et al.
PLOS ONE (2012)
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Keiko Iwaisako et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation
Radina Kostadinova et al.
CELL AND BIOSCIENCE (2012)
CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis
Kenneth E. Lipson et al.
FIBROGENESIS & TISSUE REPAIR (2012)
Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease
Dong Fan et al.
FIBROGENESIS & TISSUE REPAIR (2012)
Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis A Tale of Angiogenesis, Apoptosis, and Growth Factors
Laszlo Farkas et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2011)
Smad7: not only a regulator, but also a cross-talk mediator of TGF-β signalling
Xiaohua Yan et al.
BIOCHEMICAL JOURNAL (2011)
Idiopathic Pulmonary Fibrosis-an Epidemiological and Pathological Review
Andrea T. Borchers et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2011)
Suppression of Innate Immunity (Natural Killer Cell/Interferon-γ) in the Advanced Stages of Liver Fibrosis in Mice
Won-Il Jeong et al.
HEPATOLOGY (2011)
PPARα Expression Protects Male Mice from High Fat-Induced Nonalcoholic Fatty Liver
Mohamed A. Abdelmegeed et al.
JOURNAL OF NUTRITION (2011)
Assessment of Myocardial Fibrosis With Cardiovascular Magnetic Resonance
Nathan Mewton et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Latent TGF-β structure and activation
Minlong Shi et al.
NATURE (2011)
PPAR-γ Ligands Repress TGFβ-Induced Myofibroblast Differentiation by Targeting the PI3K/Akt Pathway: Implications for Therapy of Fibrosis
Ajit A. Kulkarni et al.
PLOS ONE (2011)
FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
Serkan Kir et al.
SCIENCE (2011)
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
Jeffrey W. Tyner et al.
BLOOD (2010)
MMP-2 alters VEGF expression via αVβ3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells
Chandramu Chetty et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
The Origin of Fibroblasts and Mechanism of Cardiac Fibrosis
Guido Krenning et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2010)
Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases
Jae Hyun Bae et al.
MOLECULES AND CELLS (2010)
GIP and GLP-1, the two incretin hormones: Similarities and differences
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Lysyl oxidase: a potential target for cancer therapy
Siddikuzzaman et al.
INFLAMMOPHARMACOLOGY (2010)
PDGF-A, -C, and -D but not PDGF-B Increase TGF-beta 1 and Chronic Rejection in Rat Cardiac Allografts
Raimo Tuuminen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Mice that lack activity of αvβ6-and αvβ8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice
Poshala Aluwihare et al.
JOURNAL OF CELL SCIENCE (2009)
Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet
Bo Kong et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta
Toru Kawai et al.
LABORATORY INVESTIGATION (2009)
Pulmonary fibrosis: pathogenesis, etiology and regulation
M. S. Wilson et al.
MUCOSAL IMMUNOLOGY (2009)
Hypoxia Hypoxia in the pathogenesis of systemic sclerosis
Christian Beyer et al.
ARTHRITIS RESEARCH & THERAPY (2009)
The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria
Xiaoxin X. Wang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
Partial inhibition of integrin alpha v beta 6 prevents pulmonary fibrosis without exacerbating inflammation
Gerald S. Horan et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice
Elizabeth E. Girroir et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence
Laurie D. DeLeve et al.
HEPATOLOGY (2008)
PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis
Frank Eitner et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice
Weiwei Shan et al.
HEPATOLOGY (2008)
TLR4 enhances TGF-β signaling and hepatic fibrosis
Ekihiro Seki et al.
NATURE MEDICINE (2007)
Mechanistic insights from structural studies of β-catenin and its binding partners
Wenqing Xu et al.
JOURNAL OF CELL SCIENCE (2007)
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
Elisabeth M. Zeisberg et al.
NATURE MEDICINE (2007)
PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties
M. Amine Bouhlel et al.
CELL METABOLISM (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis
N. I. Chaudhary et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
NF-kappa B/PPAR gamma and/or AP-1/PPAR gamma 'on/off' switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression
Panagiotis A. Konstantinopoulos et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2007)
A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18
A Prasse et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners
S Radaeva et al.
GASTROENTEROLOGY (2006)
NAD(P)H oxidase 4 mediates transforming growth factor-β1-induced differentiation of cardiac fibroblasts into myofibroblasts
I Cucoranu et al.
CIRCULATION RESEARCH (2005)
ICG-001, A Novel Small Molecule Regulator of TCF/β-Catenin Transcription
Masakatsu Eguchi et al.
MEDICINAL CHEMISTRY (2005)
Modulation of the TGFβ/Smad signaling pathway in mesangial cells by CTGF/CCN2
NA Wahab et al.
EXPERIMENTAL CELL RESEARCH (2005)
Structural basis for fibroblast growth factor receptor activation
M Mohammadi et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats
T Toyama et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Connective-tissue growth factor modulates WNT signalling and interacts with the WNT receptor complex
S Mercurio et al.
DEVELOPMENT (2004)
Peroxisome proliferator-activated receptor-α and receptor-γ activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension
M Iglarz et al.
HYPERTENSION (2003)
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension
M Iglarz et al.
HYPERTENSION (2003)
Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis
JA Holt et al.
GENES & DEVELOPMENT (2003)
Myofibroblast differentiation by transforming growth factor-β1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase
VJ Thannickal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Induction of hepatic ABC transporter expression is part of the PPAR alpha-mediated fasting response in the mouse
T Kok et al.
GASTROENTEROLOGY (2003)
Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells
K Hellemans et al.
GASTROENTEROLOGY (2003)
Estradiol reverses TGF-β1-induced mesangial cell apoptosis by a casein kinase 2-dependent mechanism
O Negulescu et al.
KIDNEY INTERNATIONAL (2002)
Myofibroblasts and mechano-regulation of connective tissue remodelling
JJ Tomasek et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis
M Kolb et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Cholangiocyte biology and cystic fibrosis liver disease
AP Feranchak et al.
SEMINARS IN LIVER DISEASE (2001)
Roles of PPARs in health and disease
S Kersten et al.
NATURE (2000)
Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor
BA Laffitte et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
